Published in Clin Pharmacol Ther on September 01, 1983
Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother (2004) 4.54
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ (1987) 1.43
A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol (1988) 1.22
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother (2009) 1.04
The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol (1994) 0.95
Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A (1987) 4.04
Malaria eradication on islands. Lancet (2000) 3.51
Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med (1984) 3.49
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Abolition of cost-sharing is pro-poor: evidence from Uganda. Health Policy Plan (2005) 2.57
Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci U S A (1984) 2.52
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr (1982) 2.40
Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg (2001) 2.34
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol (2004) 2.15
Chloroquine-resistant falciparum malaria in Madagascar and Kenya. Ann Trop Med Parasitol (1981) 2.03
[Tetanus with a deep wound?]. Lakartidningen (1994) 1.92
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis (1999) 1.81
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop (2003) 1.80
Fever episodes in a holoendemic malaria area of Tanzania: parasitological and clinical findings and diagnostic aspects related to malaria. Trans R Soc Trop Med Hyg (1993) 1.79
Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol (1983) 1.77
Adverse effects of extradural and intrathecal opiates: report of a nationwide survey in Sweden. Br J Anaesth (1982) 1.77
Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev (1989) 1.73
Agranulocytosis associated with malaria prophylaxis with Maloprim. Br Med J (Clin Res Ed) (1983) 1.72
Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. J Clin Pharm Ther (2003) 1.71
Pruritus and antimalarial drugs in Africans. Lancet (1989) 1.70
Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother (1982) 1.65
Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health (1996) 1.65
Assessing health worker performance in malaria case management of underfives at health facilities in a rural Tanzanian district. Trop Med Int Health (2007) 1.64
Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg (1992) 1.63
Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study. BMJ (1990) 1.62
Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther (2005) 1.59
Malaria chemoprophylaxis with mefloquine. Lancet (1991) 1.55
Blood pressure, hypertension and correlates in urbanised workers in Ibadan, Nigeria: a revisit. J Hum Hypertens (1999) 1.54
Characterization of the humoral immune response in Plasmodium falciparum malaria. I. Estimation of antibodies to P. falciparum or human erythrocytes by means of microELISA. Clin Exp Immunol (1983) 1.54
The concentration of chloroquine in serum during short and long term malaria prophylaxis with standard and 'double' dosage in non-immunes: clinical implications. Ann Trop Med Parasitol (1979) 1.51
Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci U S A (1986) 1.51
The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus. Clin Pharmacol Ther (2000) 1.48
Parenteral sulphadoxine-pyrimethamine (Fansidar): an effective and safe but under-used method of anti-malarial treatment. Trans R Soc Trop Med Hyg (1991) 1.48
Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet (1987) 1.46
Polyethylene particles stimulate monocyte chemotactic and activating factor production in synovial mononuclear cells in vivo. An immunohistochemical study in rabbits. Acta Orthop Scand (1995) 1.44
Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ (1987) 1.43
Malaria prophylaxis policy for travellers from Europe to the Indian Subcontinent. Malar J (2006) 1.42
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Personalizing healthcare: from genetics through payment to improving care? J R Soc Med (2013) 1.40
The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand (1998) 1.40
Anti-Plasmodium falciparum antibodies acquired by residents in a holoendemic area of Liberia during development of clinical immunity. Am J Trop Med Hyg (1986) 1.40
Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther (1980) 1.39
Availability of insulin pump therapy in clinical practice. Diabet Med (2012) 1.38
Malaria in Nigeria: a revisit. Ann Trop Med Parasitol (1990) 1.38
Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol (1996) 1.35
Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction. Trans R Soc Trop Med Hyg (1999) 1.34
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
Pneumocystis carinii pneumonia: detection of parasites in sputum and bronchoalveolar lavage fluid by monoclonal antibodies. BMJ (1988) 1.34
Synergism of benflumetol and artemether in Plasmodium falciparum. Am J Trop Med Hyg (1999) 1.33
Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol (1984) 1.32
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ (2003) 1.31
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal (2007) 1.27
Reduced uptake of ciprofloxacin in a resistant strain of Neisseria gonorrhoeae and transformation of resistance to other strains. J Antimicrob Chemother (1991) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and beta-thalassaemia traits. Ann Trop Med Parasitol (1983) 1.24
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.24
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther (1985) 1.21
In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1991) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Changes in erythrocyte sedimentation rate, C-reactive protein and hematological parameters in patients with acute malaria. Scand J Infect Dis (1989) 1.20
Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop (2006) 1.19
Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop (1998) 1.19
Different malaria control activities in an area of Liberia--effects on malariometric parameters. Ann Trop Med Parasitol (1985) 1.19
Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol (2004) 1.18
Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct gammadelta+ T cell patterns in Plasmodium falciparum and P. vivax infections. Clin Exp Immunol (1997) 1.14
Falciparum malaria and beta-thalassaemia trait in northern Liberia. Ann Trop Med Parasitol (1983) 1.14
Long-term survival in transfusion recipients in Sweden, 1993. Transfusion (2001) 1.12
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
Resorption of hydroxyapatite and fluorapatite ceramic coatings on weight-bearing implants: a quantitative and morphological study in dogs. J Biomed Mater Res (1998) 1.11
Present state of extradural and intrathecal opioid analgesia in Sweden. A nationwide follow-up survey. Br J Anaesth (1987) 1.11
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther (1998) 1.11
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol (1987) 1.11
Human monoclonal antibodies to Pf 155, a major antigen of malaria parasite Plasmodium falciparum. Science (1986) 1.11
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics (1999) 1.09
Pharmacokinetics of fluoride in man after single and multiple oral doses. Eur J Clin Pharmacol (1977) 1.09
The in vivo sensitivity of Plasmodium falciparum to chloroquine and to sulphadoxine-pyrimethamine combination in Ibadan, Nigeria. Trans R Soc Trop Med Hyg (1981) 1.09
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur J Cancer (2004) 1.08
Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br (2005) 1.08
Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. Br Med J (Clin Res Ed) (1987) 1.08
References used in a drug information centre. Eur J Clin Pharmacol (1995) 1.08
Cerebral malaria in non-paediatric subjects resident in southwestern Nigeria. Afr J Med Med Sci (1993) 1.08
Effect of different fractions of heparin on Plasmodium falciparum merozoite invasion of red blood cells in vitro. Am J Trop Med Hyg (1992) 1.08